Search Within

Charles Ryan

  1. "Genitourinary Oncology Service"
Formats
  1. Meeting Abstract (6)
  2. Journal Article (5)
Groups
  1. Department of Medicine (11)
  2. Genitourinary Oncology Service (11)
  3. Solid Tumor Oncology Division (11)
  4. Biostatistics Service (6)
  5. Epidemiology and Biostatistics (6)
  6. Department of Pathology and Laboratory Medicine (4)

More Groups

People
  1. Howard Scher (7)
  2. Alexander Smith (4)
  3. Jaya Satagopan (4)
  4. Michael Morris (4)
  5. Peter Scardino (4)
  6. Priti Lal (4)

More People

Years
  1. 2025 (3)
  2. 2014 (1)
  3. 2007 (1)
  4. 2006 (1)
  5. 2004 (2)
  6. 2003 (2)

More Years

Publications
  1. Journal of Clinical Oncology (4)
  2. Urology (2)
  3. American Journal of Pathology (1)
  4. Journal of Urology (1)
  5. Laboratory Investigation (1)
  6. Modern Pathology (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (4)
  2. Elsevier Science, Inc. (4)
  3. Nature Publishing Group (1)
  4. Nature Research (1)
  5. W.B. Saunders Co. (1)

Results (11)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Racial differences in organic anion transport proteins (OATP) and outcome in castration resistant prostate cancer treated with AR pathway inhibitors in Alliance A031201: A phase III trial
    Meeting Abstract

    Ryan, C. J.; Kim, H.; Morris, M. J.; Alyamani, M.; Diaz, R.; Beltran, H.; Armstrong, A. J.; Sharifi, N.; Halabi, S.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Adrenal androgens and overall survival (OS) in men with castration-resistant prostate cancer (CRPC) treated with enzalutamide without (ENZ) or with abiraterone and prednisone (ENZ/AAP) (Alliance)
    Meeting Abstract

    Sharifi, N.; Kim, H.; Alyamani, M.; Diaz, R.; Beltran, H.; Armstrong, A. J.; Morris, M. J.; Halabi, S.; Ryan, C. J.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Analysis of distinct genomic, transcriptomic, and immune landscapes driven by alterations in androgen production, uptake, and conversion (APUC) genes in metastatic prostate cancers
    Meeting Abstract

    Lacuna, K. P.; Ishani, K.; Boytim, E.; Abida, W.; Morris, M. J.; Antonarakis, E. S.; Hwang, J.; Ryan, C. J.
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Does Gleason score (GS) predict efficacy of abiraterone acetate (AA) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials
    Meeting Abstract

    Fizazi, K.; Flaig, T. W.; Ohlmann, C. H.; Scher, H. I.; de Bono, J. S.; Rathkopf, D. E.; Ryan, C. J.; Kheoh, T. S.; Li, J. H.; Todd, M. B.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer
    Journal Article

    Morris, M. J.; Kelly, W. K.; Slovin, S.; Ryan, C.; Eicher, C.; Heller, G.; Scher, H. I.
    Journal of Urology (2007)

    Fulltext@MSK | Save
  • Persistent prostate-specific antigen expression after neoadjuvant androgen depletion: An early predictor of relapse or incomplete androgen suppression
    Journal Article

    Ryan, C. J.; Smith, A.; Lal, P.; Satagopan, J.; Reuter, V.; Scardino, P.; Gerald, W.; Scher, H. I.
    Urology (2006)

    Fulltext@MSK | Save
  • Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance
    Journal Article

    Holzbeierlein, J.; Lal, P.; LaTulippe, E.; Smith, A.; Satagopan, J.; Zhang, L.; Ryan, C.; Smith, S.; Scher, H.; Scardino, P.; more...
    American Journal of Pathology (2004)

    Fulltext@MSK | Save
  • Five-year outcomes after neoadjuvant chemotherapy and conformal radiotherapy in patients with high-risk localized prostate cancer
    Journal Article

    Ryan, C. J.; Zelefsky, M. J.; Heller, G.; Regan, K.; Leibel, S. A.; Scher, H. I.; Kelly, W. K.
    Urology (2004)

    Fulltext@MSK | Save
  • Transcriptional programs affected by androgen ablation therapy and the development of therapy resistant prostate cancer
    Meeting Abstract

    Lal, P.; Holzbeierlein, J.; LaTulippe, E.; Satagopan, J.; Smith, A.; Ryan, C.; Scher, H.; Scardino, P.; Reuter, V.; Gerald, W.
    Laboratory Investigation (2003)

    Fulltext@MSK | Save
  • Transcriptional programs affected by androgen ablation therapy and the development of therapy resistant prostate cancer
    Meeting Abstract

    Lal, P.; Holzbeierlein, J.; LaTulippe, E.; Satagopan, J.; Smith, A.; Ryan, C.; Scher, H.; Scardino, P.; Reuter, V.; Gerald, W.
    Modern Pathology (2003)

    Fulltext@MSK | Save